Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Gan & Lee Insulin Glargine vs Lantus in T1DM
NCT02506647Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glargine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Pharmacodynamic effects and Pharmacokinetic effects. Started Dec 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02506647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506647.